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ABSTRACT
HNF1β is expressed exclusively in ovarian clear cell carcinoma (OCCC) and not in 
other ovarian cancers, regarded as a hallmark of this tumor. This implies its central 
role in the unique character of OCCC, including resistance to chemotherapy, but its 
exact role and influence in cancer biology or the molecular bases of its function 
are largely unknown. Using comprehensive metabolome analysis of HNF1β_shRNA-
stable cell lines, we show here that HNF1β drastically alters intracellular metabolism, 
especially in direction to enhance aerobic glycolysis, so called the “Warburg effect”. 
The consequence of the metabolic change contributed cell survival under stresses such 
as hypoxia and chemo-reagent, only when sufficient glucose supply was available. 
Augmented cell survival was based on the reduced ROS activity derived from metabolic 
alteration such as shift from oxidative phosphorylation to glycolysis and increased 
intracellular anti-oxidant, glutathione (GSH). One of the cystine transporters, rBAT 
is likely to play a major role in this GSH increase. These data suggest that HNF1β, 
possibly induced by stressful microenvironment in the endometriotic cyst, confers 
survival advantage to the epithelial cells, which leads to the occurrence of OCCC, 
a chemo-resistant phenotype of ovarian cancer.
INTRODUCTION
Ovarian clear cell carcinoma (OCCC) is a relatively 
rare subtype among the ovarian cancers, but is a clinically 
important entity because it is generally resistant to 
chemotherapy and is known to have a worse prognosis 
compared with other ovarian cancers [1–4]. Another 
clinical feature of OCCC is its frequent occurrence in 
endometriotic cysts, so called “chocolate cysts”. Studies 
have indicated that approximately 1% of endometriotic 
cysts give rise to ovarian cancer [5–9], and, unlike 
common ovarian cancers, which are most frequently 
serous carcinomas, cancers occurring from endometriotic 
cysts are primarily clear cell and endometrioid carcinomas 
[8–10]. However, the reason for this remains unclear.
We have shown previously that the microenvironment 
within the “chocolate cyst,” which contains high levels of 
free iron and consequently reactive oxygen species 
(ROS), is extraordinarily stressful to epithelial cells 
within the cyst [11]. ROS are one of the major causes of 
cancer development, and at the same time, cancer cells 
must cope with various external and internal ROS for 
survival [12]. In addition to external ROS, an increased 
requirement for energy accompanied by proliferative 
tumor growth produces high levels of internal ROS 
through the mitochondrial respiratory chain [13, 14]. To 
avoid cell damage from these external and internal ROS, 
cells possess scavenger systems to eliminate ROS and 
minimize damage [15–18]. Indeed, the choice between 
cell survival and death depends on the balance between 
ROS production and potential for elimination.
We have also shown that OCCC has a unique 
gene expression profile consisting of many stress-related 
genes. Specifically, we suggested that the transcription 
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factor HNF1β (hepatocyte nuclear factor 1 homeobox B), 
a gene specifically expressed in OCCC, distinguishes 
this phenotype from other ovarian cancers [19, 20]. 
HNF1β is a transcription factor which shares strong 
homology with HNF1α. Functionally, it is associated with 
developmental process of liver, pancreas and kidney. 
Clinically, heterozygous germline mutations in HNF1β 
is responsible for a familial forms of type 2 diabetes 
designated as maturity-onset diabetes of the young, 
subtype 5 (MODY5), which is often associated with 
congenital abnormalities such as polycystic kidney, 
pancreatic hypoplasia and genital tract abnormality [21].
In addition, overexpression of HNF1β has been 
reported in multiple malignancies including OCCC. 
So far, reported function of HNF1β includes epithelial 
morphogenesis and differentiation [22], regulation of urate 
transporter and organic anion transporters [23]. Kornfeld 
et. al. showed that HNF1β knockdown in mouse liver cells 
caused gluconeogenesis [24], suggesting that HNF1β has 
strong relation with glucose metabolism. However, precise 
mechanism how HNF1β contributes cancer biology 
remains to be elucidated.
We have previously demonstrated that HNF1β 
activates glycolysis and increases lactate production 
in OCCC cell line, RMG2 [25]. Regarding the unique 
glucose metabolism in cancer, Otto Warburg reported in 
1956 that cancer cells prefer to metabolize glucose by 
glycolysis even in the presence of adequate oxygen [26]. 
This seemingly paradoxical phenomenon is called the 
Warburg effect and is now known as a metabolic hallmark 
of cancer cells, but its causal relationship with cancer 
progression remains largely unknown [12, 27–29]. One 
compelling explanation of the Warburg effect is that cancer 
cells gain survival advantage, such as ROS resistance and 
consequent apoptosis inhibition [12, 16, 27, 28], supply 
of biosynthetic substrates [12, 15, 16, 28], and oxygen-
independent energy production [12, 15, 16, 28].
In this study, we hypothesized that HNF1β, which is 
expressed exclusively in OCCC confer anti-ROS activity 
by altering glucose metabolism, thereby contributing to 
carcinogenesis in high ROS environment of endometriotic 
cysts and cell survival in OCCC. We attempted to explore 
the full extent of the metabolic alterations caused by 
HNF1β in OCCC using a comprehensive metabolic assay. 
Additionally, we investigated the biological influences of 
these alterations.
RESULTS
OCCC had a unique metabolic feature compared 
with other histological subtypes of EOC
To identify characteristics specific for the OCCC 
subtype, we first performed gene set enrichment analysis 
(GSEA: http://www.broadinstitute.org/gsea/index.jsp) 
using the microarray datasets GSE39204, which contain 
64 ovarian cancer clinical samples from Kyoto University 
Hospital, and GSE6008, which contain 99 ovarian cancer 
clinical samples [30]. The samples in each dataset were 
divided into the OCCC group and the non-OCCC group, 
and gene sets enriched in the OCCC group were extracted 
and analyzed.
In GSE39204, 46 gene sets enriched in the OCCC 
group contained 15 metabolic activity-related gene 
sets. In GSE6008, 72 gene sets enriched in the OCCC 
group contained 13 metabolic activity-related gene sets. 
Among the 24 gene sets enriched both in GSE39204 and 
GSE6008, 9 metabolic activity-related gene sets were 
present. The ratio of metabolic activity-related gene sets 
in these groups was significantly higher than the ratio in 
the total gene sets (Msig DB C5_all v4.0) (GSE39204: 
p < 0.0001, GSE6008: p = 0.0223, both: p < 0.0001) 
(Fig. 1, detailed data are shown in Table S1a and S1b).
In addition, GSEA revealed that 2 transcription 
motifs of HNF1 (hepatocyte nuclear factor 1) and SF1 
(splicing factor 1) were enriched in the OCCC group in 
both GSE39204 and GSE6008 (Msig DB C3.tft.v4.0) 
(Table S1c), which suggested that these transcription 
factors may be associated with the unique metabolic 
features of OCCC (Fig. 1).
HNF1β drastically changed intracellular glucose 
metabolites
To explore the influence of HNF1β on metabolic 
activity in OCCC, we performed comprehensive 
in vitro analysis of intracellular metabolism in HNF1β 
knockdown RMG2 cells (HNF1β_sh1) and control cells 
(control) that were established as described [25]. A total 
of 193 peaks were identified as candidate metabolites by 
this assay, of which 88 metabolites were significantly 
altered in HNF1β_sh1 cells. Of these, 52 metabolites 
were decreased by at least 0.7-fold and 20 were increased 
by at least 1.4-fold (Table S2a & S2b). Specifically, 
lactic acid, the final product of anaerobic glycolysis, 
was significantly decreased in HNF1β_sh1 cells. In 
contrast, citric acid, the first metabolite of the TCA 
cycle following integration of acetyl CoA into this cycle 
from the glycolytic process, was significantly increased 
in HNF1β_sh1 cells (p < 0.05 for both), and malic acid 
that was to be converted to citric acid if pyruvic acid was 
provided to the TCA cycle via acetyl CoA, was decreased, 
suggesting that oxidative phosphorylation is more active 
in these cells (or less active in HNF1β-high cells by 
acetyl CoA supply stagnation) (Fig. 2a). Regarding as 
lactic acid decrease in HNF1β_sh1 cells, there are other 
mechanisms that could control the lactic acid level 
such as lactic acid transporters and another lactic acid 
synthesis pathway. However, in microarray analysis, the 
expression of SLC16A1 that encodes lactic acid import 
transporter MCT1 was high, and that of SLC16A3 that 
encodes lactic acid export transporter MCT4 was low in 
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Figure 1: Gene expressions enriched in OCCC detected by GSEA analysis between OCCC and non-OCCC. The 
microarray datasets GSE39204 and GSE6008 were divided into the OCCC group and the non-OCCC group, and analyzed using GSEA. 
In GSE39204, 46 gene sets were enriched in the OCCC group. In GSE6008, 72 gene sets were enriched in the OCCC group. 24 gene sets 
were enriched in both GSE39204 and GSE6008, in which 9 were metabolic activity-related. In addition, 2 transcription motifs of HNF1 
and SF1 were enriched in the OCCC group in both GSE39204 and GSE6008. Detailed data including individual gene sets are shown in 
Supplementary Table 1a – 1c.
HNF1β_sh1 cells and in non-clear cell samples (Fig. S1), 
suggesting that lactic acid transporters expressed not to 
decrease lactic acid, but to compensate it. With respect 
to the pathway for lactic acid synthesis from pyruvate 
via glucose-alanine cycle, in spite of low level of lactic 
acid, both the alanine and pyruvate showed high level in 
HNF1β_sh1 cells in the metabolome analysis (Fig. S2). 
These results collectively suggested that lactic acid 
accumulation in HNF1β-high control cells is derived from 
increased glycolysis, but not from other mechanisms. 
Conclusively, it is suggested that HNF1β causes a 
metabolic shift from the TCA cycle to glycolysis. In 
contrast, regarding the pentose-phosphate-pathway (PPP), 
which is generally activated by aerobic glycolysis and 
thought to supply lipid and nucleotide substrates, neither 
6 phosphogluconic acid (6 PG), the first metabolite of 
PPP, nor NADPH, the key substrate of lipid synthesis, 
were significantly changed (Fig. 2a). As for nucleotide 
synthesis, uric acid, the last product of nucleotide 
metabolism, increased significantly in HNF1β_sh1 
cells (p < 0.0001) (Fig. 2a), which might be the result 
of significant G6PD increase. These data indicated 
that HNF1β does not activate PPP even during aerobic 
glycolysis. Likewise, regarding as the energy supply that 
is thought to be supported by aerobic glycolysis under 
certain conditions, neither ATP nor energy charge levels 
((ATP+1/2ADP) / (ATP+ADP+AMP)) were significantly 
changed (Fig. 2b).
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Figure 2: Comparison of intracellular metabolism between HNF1β-high control cells and HNF1β knockdown cells by 
comprehensive metabolic analysis. Control: RMG2 control cells, HNF1β_sh1 : RMG2 HNF1β_sh1 cells. The amount of metabolites 
used was pmol /106 cells. n = 3. a. Comparison of glucose metabolism including glycolysis and oxidative phosphorylation (TCA cycle) 
between RMG2 control cells and HNF1β_sh1 cells. b. Comparison of energy charge between RMG2 control cells and HNF1β_sh1 cells.
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We also assessed the expression levels of the 
HK1, G6PD, and LDHA genes, which are assumed to 
be related to aerobic glycolysis. In HNF1β_sh1 cells, 
the expression of HK1 and LDHA was significantly 
decreased (p < 0.0001), but the expression of G6PD 
was significantly increased (p < 0.0001) (Fig. S3a). 
In addition, based on analysis of the clinical dataset 
GSE39204, HK1 and LDHA were significantly higher 
in the OCCC group than in the non-OCCC group, and 
they were significantly correlated with the expression of 
HNF1β (p < 0.0001). There was no significant difference 
in the expression of G6PD between the two groups 
(Fig. S3b).
HNF1β expression allowed OCCC cells to 
survive in hypoxic conditions
We performed functional assays using 2 types of 
HNF1β knockdown lines (HNF1β_sh1, sh2) of both 
RMG2 and JHOC5 OCCC cells (Fig. S4a & S4b). To 
explore whether HNF1β expression is associated with 
cell adaptation to hypoxia, we performed WST assays 
in both 2% and 20% O2. In RMG2 cell lines, the number 
of live HNF1β knockdown cells significantly decreased 
in 2% O2 compared to those in 20% O2. In contrast, in 
both RMG2 and JHOC5 cell lines, HNF1β-high control 
cells showed increased number of live cells in 2% O2 
(Fig. 3a & 3b). We further assessed the chemo-resistance 
of RMG2 and JHOC5 cells under hypoxic conditions. 
Cell survival, which was assessed by the ratio of the 
number of cells alive after 24 hours exposure to 20, 
40, or 80 μM CDDP to the number of cells alive after 
24 hours without CDDP, was significantly decreased 
in HNF1β knockdown cells (p < 0.01 for both cell 
types) (Fig. 3c & 3d). Furthermore, JHOC5 cells, 
under hypoxic condition, showed significantly low 
IC50 of CDDP in HNF1β knockdown cells (p < 0.02) 
(Fig. 3e).
HNF1β-induced cell survival was abrogated 
under glucose deprivation
Control, HNF1β_sh1, and HNF1β_sh2 RMG2 
cells were cultured in normal growth medium (glucose 
(+) medium) and in glucose-deprivation medium 
(glucose (−) medium) in normoxic condition, and cell 
numbers were measured every 24 hours by WST-8 assay. 
In glucose (+) medium, HNF1β_sh1, and HNF1β_sh2 
RMG2 cells had similar number compared with control 
cells (Fig. 4a). By contrast, in glucose (−) medium, 
the number of live cells were significantly less in 
control RMG2 which had high HNF1β expression 
(Fig. 4b, 4c, & 4d), suggesting that HNF1β-induced 
cell survival effect is highly dependent on the glucose 
supply.
HNF1β reduced intracellular ROS and 
contributed to oxidative stress resistance
The oxygen independent nature of aerobic 
glycolysis also provides an advantage by decreasing 
oxidative phosphorylation in the TCA cycle, which is the 
main source of intracellular ROS.
To explore whether HNF1β expression is associated 
with ROS regulation and consequent resistance to 
oxidative stress, we performed HNF1β redox functional 
assays. HNF1β knockdown significantly increased 
intracellular ROS activity levels in both RMG2 and 
JHOC5 (p < 0.001) (Fig. 5a & 5d). Moreover, when 
these cells were cultured in conditions with extracellular 
oxidative stress such as medium containing ferric 
nitrilotriacetate (FeNTA), an iron chelate, or H2O2, a 
well-known extra/intracellular oxidative agent, increase 
in intracellular ROS activity was significantly more 
prominent in HNF1β knockdown cells (p < 0.005) 
(Fig. 5a – 5e). This consequently decreased the IC50 of 
FeNTA in HNF1β knockdown cells (Fig. 5f).
HNF1β expression was associated with 
intracellular GSH levels
To elucidate ROS regulation by HNF1β, we further 
evaluated the metabolism of intracellular glutathione 
(GSH), a primary intracellular redox regulator. 
Metabolome analysis in RMG2 cells showed that 
intracellular GSH significantly decreased in HNF1β_sh1 
cells (p < 0.0005) (Fig. 6a). In GSH substrates, cysteine, 
which is the rate-limiting metabolite of GSH synthesis, 
decreased, glutamate was not altered, and glycine 
significantly increased in HNF1β_sh1 cells (HNF1β_
sh1 /control: 0.60 (p = 0.158), 097 (p = 0.470), 1.21 
(p < 0.001), respectively) (Fig. 6a). We confirmed the 
results of the metabolome analysis by another method in 
RMG2 and JHOC5. Using an enzyme recycling method, 
we assessed total intracellular GSH and the ratio of 
GSSG (the oxidized form of GSH) to total GSH. HNF1β 
knockdown significantly decreased intracellular GSH and 
increased the ratio of GSSG to total GSH (Fig. 6b & 6c). 
These results indicate that HNF1β increases intracellular 
GSH and, thus, enhances the redox potential of OCCC 
cells.
Next, we investigated the mechanism by which 
HNF1β increased intracellular GSH levels. Messenger 
RNA expression levels of GSH synthesis-related 
synthases, including glutamate-cysteine ligase regulatory 
subunit (GCLM), glutamate-cysteine ligase catalytic 
subunit (GCLC), and glutathione synthase (GS), as well 
as GSH transporters of the substrates glutamate, glycine, 
and cysteine, were analyzed by microarray. Among the 
synthase-coding genes, only GCLC expression was 
significantly decreased in the RMG2 HNF1β_sh1 cells 
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Figure 3: HNF1β knockdown impairs adaptation of OCCC cells to hypoxic conditions. a, b. Comparison of cell survival in 
hypoxia among control, HNF1β_sh1, and HNF1β_sh2 cells. (a) RMG2 and (b) JHOC5 cells were cultured in both 20% O2 and 2% O2 and 
number of live cells was measured by the WST-8 method. n = 10. c, d. CDDP resistance in 2% O2 conditions. Control, HNF1β_sh1, and 
HNF1β_sh2 cells were exposed to 0, 20, 40, or 80 μM CDDP for 24 hours. Cell survival was calculated as the WST-8 value of CDDP 20, 
40, or 80 μM divided by that in the absence of CDDP (0 μM CDDP) in (c) RMG2 and (d) JHOC5 cells. n = 10. e. CDDP dose response 
curve and IC50 of JHOC5 cell lines.
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(p < 0.05) (Fig. 6d), whereas it was not significantly 
associated with HNF1β expression in the clinical dataset 
GSE39204 (Fig. 6e). Moreover, none of the synthases 
displayed significantly higher expression in the OCCC 
group (Fig. 6e). In contrast, among the GSH substrate-
related transporter-coding genes, rBAT / SLC3A1, which 
encoded a subunit of the b0,+ amino acid transporter, was 
significantly decreased by HNF1β knockdown (p < 0.001) 
(Fig. 6f). Furthermore, rBAT was significantly higher in 
the OCCC group and was also significantly correlated with 
HNF1β expression (p < 0.001) (Fig. 6g).
HNF1β induced rBAT expression increased 
intracellular GSH in OCCC
In GSH synthesis, cysteine is known to be the rate-
limiting substance because the total levels of cysteine are 
much lower in cells than the levels of other molecules. 
Most intracellular cysteine is taken into cells in its 
oxidized form, cystine. Therefore, we investigated whether 
the cystine supply altered intracellular GSH. Indeed, 
decreasing the cystine supply by altering the cystine 
concentration in the growth medium reduced intracellular 
GSH (Fig. 7a).
The cystine supply is generally regulated by cystine 
transporters in live cells. One of these transporters, 
rBAT (related to b0,+ amino acid transporter), was 
significantly decreased by HNF1β knockdown (p < 0.001) 
(Fig. 6f & 7b). Expression of rBAT protein was also 
decreased by HNF1β knockdown in both RMG2 and 
JHOC5 cells (Fig. 7c).
Based on these findings, we further investigated 
whether induction of rBAT by HNF1β led to GSH synthesis, 
using 2 types of rBAT knockdown lines (rBAT_sh1, sh2) of 
both RMG2 and JHOC5 OCCC cells (Fig. S4c & S4d). 
rBAT knockdown significantly reduced intracellular GSH 
Figure 4: HNF1β knockdown rescued the cell survival under glucose deprivation. a, b. Control, HNF1β_sh1, and HNF1β_sh2  
RMG2 cells were cultured (a) in normal growth medium (glucose (+) medium) and (b) in glucose-deprivation medium (glucose (-) medium) 
in normoxic condition, and cell numbers were measured every 24 hours by WST-8 assay. The WST-8 value rate was calculated as the WST-
8 value in 0, 24, or 48 hours divided by that in 0 h. c, d. Cell number percentages of glucose (-) / glucose (+) medium were calculated using 
the WST-8 values of each cells (c) in 24 hours culture and (d) in 48 hours culture respectively.
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Figure 5: HNF1β knockdown increases intracellular ROS and decreases resistance to oxidative stress in OCCC 
cells. The intracellular ROS activity level of control, HNF1β_sh1, and HNF1β_sh2 cells (both RMG-2 and JHOC5) was detected by 
CellROX® Deep Red Reagent and measured by flow cytometry. a. RMG2 cell lines were cultured in normal medium, in medium with 
0.5 mM FeNTA for 2 hours, and in medium with 0.5 mM H2O2 for 1 hour. Intracellular ROS activity levels of them were assessed by MFI 
(mean fluorescence intensity). n = 6. b. ROS increase by FeNTA in each cell lines was determined as (MFI of intracellular ROS activity 
in medium with 0.5 mM FeNTA) – (MFI of intracellular ROS activity in normal medium). c. ROS increase of each RMG2 cells by H2O2. 
d. Intracellular ROS activity levels of JHOC5 cell lines cultured in normal medium and in medium with 0.5 mM FeNTA for 2 hours. n = 6. 
e. ROS increase of each JHOC5 cells by FeNTA. f. FeNTA IC50 value for RMG2 and JHOC5 cells.
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Figure 6: HNF1β knockdown decreases intracellular GSH levels via expression of the cystine transporter rBAT. a. GSH 
synthesis pathway in the metabolome analysis. Control: RMG2 control cells, HNF1β_sh1 : RMG2 HNF1β_sh1 cells. n = 3. b, c. Intracellular 
GSH and the ratio of GSSG to total GSH in control, HNF1β_sh1, and HNF1β_sh2 cells of (b) RMG2 and (c) JHOC5. They were measured 
by the enzyme recycling method. d, f. Expressions of (d) GSH synthesis related genes (GSS, GCLM, and GCLC) and (f) a cystine transporter 
subunit coding gene rBAT were analyzed using the microarray dataset GSE37290 (RMG2 control, HNF1β_sh1 cell lines). e, g. Differences 
in expression levels of (e) GSH synthesis related genes and (g) rBAT between the OCCC group (clear) and the non-OCCC group (non-
clear) were analyzed using the clinical ovarian cancer dataset GSE39204. The correlations of their expressions with that of HNF1β were 
additionally shown (lower columns).
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both in RMG2 and in JHOC5 cells (Fig. 7d). Moreover, the 
intracellular ROS activity level was significantly increased 
by rBAT knockdown with or without external oxidative 
stress by FeNTA (p < 0.0001) (Fig. 7e & 7f). These results 
indicate that rBAT expression decreases intracellular ROS 
activity by promoting GSH synthesis.
DISCUSSION
It is well known that cancer cells have unusual 
metabolic patterns relative to normal cells. A common 
example of this is the intracellular metabolic shift from 
oxidative phosphorylation to glycolysis, which is called 
the Warburg effect [27–29]. Although the Warburg effect 
is a universally observed phenomenon in various types of 
cancer cells [31–33], its causal relationship with cancer 
biology remains unclear. We have previously shown that 
HNF1β, a molecule that is expressed in high frequency 
and specificity in OCCC, facilitates glucose uptake and 
promotes concomitant glycolysis, leading to increased 
lactic acid production [25]. In this study, we started by 
confirming our previous observation [19, 20, 34] that 
OCCC has a characteristic gene expression profile that 
specifically includes enriched metabolism-related genes. 
Indeed, HNF1 transcription motif and metabolism-related 
Figure 7: rBAT knockdown decreases intracellular GSH and increases intracellular ROS activity. a. RMG2 and JHOC5 
cells were cultured in the growing medium with 0, 0.001, 0.01, 0.1, and 0.2 mM cystine respectively, and intracellular GSH of each cells 
were measured using the enzyme recycling method. n = 6. b. Expression levels of rBAT mRNA in control, HNF1β_sh1, HNF1β_sh2 cell 
lines of RMG2 and JHOC5 were detected by RT-PCR. n = 4. c. Western blotting of rBAT protein in control, HNF1β_sh1, HNF1β_sh2 
cell lines of RMG2 and JHOC5. d. Intracellular GSH in control, rBAT_sh1, and rBAT_sh2 cells of RMG2 and JHOC5, measured by the 
enzyme recycling method. n = 6. e, f. Intracellular ROS activity levels detected by CellROX® Deep Red Reagent and measured by flow 
cytometry. RMG2 and JHOC5 control, rBAT_sh1, and rBAT_sh2 cells were cultured (e) in normal growth medium and (f) in medium with 
0.5 mM FeNTA for 2 hours. n = 6.
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gene sets were enriched in OCCC based on GSEA analysis 
using ovarian cancer data sets GSE39204 and GSE6008 
(Fig. 1 & Table S1a – S1c). These data led us to investigate 
the broader spectrum of metabolic activity associated with 
HNF1β, using a comprehensive metabolite analysis. In 
addition, we attempted to elucidate the mechanism and 
biological consequence of the unique metabolism caused 
by HNF1β.
Comprehensive intracellular metabolites analysis 
revealed that HNF1β dynamically altered intracellular 
metabolism. First, we focused on glucose metabolism. 
As we have previously reported [25], lactic acid, the 
final product of anaerobic glycolysis, was significantly 
decreased in HNF1β knockdown cells (Fig. 2a). 
Supportively we confirmed that this lactic acid decrease 
was not caused by altered lactic acid transport, or 
another synthetic pathway. Although facilitated lactic 
acid accumulation by lactic acid transporter MCTs 
(Monocarboxylate Transporters) was reported in some 
cancers [35, 36], the expression of lactic acid import 
transporter MCT1 was low, and the lactic acid export 
transporter MCT4 was high in HNF1β-high cells (Fig. S1). 
Alanine or pyruvate, intermediates of another lactic acid 
synthesis pathway, also did not increase in metabolome 
assay in HNF1β-high cells (Fig. S2 & 2a). These results 
indicated that HNF1β, by glycolysis, increased lactic 
acid production and accumulation, which consequently 
caused upregulation of lactic acid export. At the same 
time, citric acid, the first metabolite of the TCA cycle 
following integration of acetyl CoA into this cycle 
from the glycolytic process, was significantly increased 
(Fig. 2a). The process converting malic acid to citric acid 
is impaired, leading to malic acid accumulation in HNF1β-
high OCCC cells (Fig. 2a). These results suggest that 
HNF1β overexpression in OCCC leads to the metabolic 
shift from oxidative phosphorylation in the TCA cycle to 
glycolysis even in aerobic condition, namely, the Warburg 
effect.
In addition to the results of metabolome analysis, 
microarray data also indicated that key genes of the 
Warburg effect, such as HK1(Hexokinase-1) that 
supports glucose supply through phosphating glucose to 
glucose-6-phosphate, and LDHA that supports conversion 
pyruvate to lactic acid, [11, 37–39] were significantly 
higher in HNF1β-high OCCC cells (Fig. S3a). In the 
analysis of the clinical dataset GSE39204, HK1 and LDHA 
were also expressed at higher levels in the OCCC group 
than in the non-OCCC group. Expression levels of these 
genes were correlated significantly to the expression of 
HNF1β (p < 0.0001) (Fig. S3b). Collectively, these results 
suggest that HNF1β contributes to enhance the Warburg 
effect. There are reports indicating that activation of 
specific genes, especially oncogenes such as Ras or Akt, 
causes similar metabolic shift [28], suggesting that genetic 
events associated with cancer development occasionally 
accompany metabolic alteration.
Several advantages of the Warburg effect have 
been proposed in cancer cells [12, 16, 26–28], one of 
which is energy support. Although anaerobic glycolysis 
is inefficient in energy production, it enables cells to 
acquire needed energy more rapidly than with oxidative 
phosphorylation in TCA cycle, both in aerobic and 
anaerobic conditions as long as abundant glucose is 
provided [12, 16]. Since a majority of the cancer cells 
grow rapidly than normal cells, they usually require 
excessive energy support. However, in this study, we 
found no evidence that HNF1β increased intracellular 
energy supplies at least under normoxic conditions 
(Fig. 2b). A second possible advantage of the Warburg 
effect is the supply of substrates, especially lipids and 
nucleotides, which are required for cellular proliferation. It 
is proposed that the Warburg effect activates the pentose-
phosphate-pathway which increases the supply of these 
substrates [12, 16, 28]. However, HNF1β did not seem 
to activate this pathway. Neither the levels of 6 PG, the 
first metabolite of PPP nor NADPH, the key substrate 
of lipid synthesis, were significantly changed (Fig. 2a). 
Clinically, OCCC is known as a relatively slow-growing 
tumor, which suggests that OCCC particularly does not 
necessarily need to utilize these benefits of the Warburg 
effect. These data are consistent with our previous report 
that HNF1β, unlike oncogenes, decreases cell proliferation 
of OCCC in normal oxygen condition [25]. The third 
advantage of the Warburg effect is to support cell survival 
with unstable oxygen supply in cancer microenvironments 
[12, 16, 27, 28]. In this study, HNF1β-high OCCC cells 
had a survival advantage especially under hypoxic 
conditions (Fig. 3a & 3b). Furthermore, these cells were 
also more resistant to CDDP treatment not in nomoxic 
condition but in hypoxic conditions compared with 
HNF1β knockdown cells (Fig. S5a, S5b, & 3c–3e). It is 
notable that cell survival advantage was exerted only 
under abundant glucose supply. Generally, glucose 
dependency is thought to be one of the weak points of the 
Warburg effect. Other groups have reported that glucose 
deprivation is critical in cancers displaying the Warburg 
effect [37, 47, 48]. On the other hands, it has been also 
reported that some cancers compensate ineffective energy 
production of glycolysis by energy production using 
glutamine via glutaminolysis [49, 50]. In our metabolome 
assay, however, HNF1β increased neither glutamate nor 
α-ketoglutarate (2-OG) in the pathway of glutaminolysis 
(Fig. 2a), suggesting that HNF1β does not facilitate 
glytaminolysis. As expected, survival benefit of HNF1β-
high OCCC cells was significantly impaired in glucose 
deprivation, suggesting that cell survival of HNF1β-high 
OCCC cells is highly dependent on glucose uptake and 
consumption (Fig. 4a - 4d).
Higher ROS activity readily leads to initiation 
of apoptosis. Cell survival advantage by the Warburg 
effect had been mostly ascribed to the detoxication of 
intracellular ROS. Oxidative phosphorylation in the TCA 
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cycle is the primary source of intracellular ROS, and the 
Warburg effect represses it by increasing the oxygen-
independent glycolysis [14, 17, 40, 41]. Therefore, we 
measured intracellular ROS activity in OCCC cells with 
high and low HNF1β expression. Our results indicated 
that, in normal medium, HNF1β-high OCCC cells 
had lower levels of intracellular ROS (Fig. 5a & 5d), 
suggesting that HNF1β expression is likely to reduce 
intracellular ROS activity and thereby confers ROS 
resistance in OCCC cells. Because OCCC is exposed to 
free iron-induced external ROS in endometriotic cysts, 
as we reported previously [11], we also examined the 
effect of HNF1β expression under known extracellular 
oxidative stressors such as ferric nitrilotriacetate (FeNTA) 
or H2O2. Again, under such oxidative stress, control 
OCCC cells with high HNF1β expression had lower ROS 
activity levels compared with their HNF1β knockdown 
counterparts (Fig. 5a – 5e). These data suggest that, 
HNF1β expression reduces intracellular ROS activity and 
thereby confers ROS resistance in OCCC cells, maybe by 
the direct consequence of the Warburg effect.
In addition to the suppression of oxidative 
phosphorylation, our metabolome analysis also showed 
that HNF1β knockdown is associated with a significant 
decrease in intracellular GSH, a major regulator of 
intracellular ROS (Fig. 6a - 6c) [41–43]. In addition, 
the ratio of GSSG, an oxidized form of GSH, was also 
high in HNF1β knockdown cells (Fig. 6b & 6c). This 
suggests that active intracellular GSH is more abundant 
in HNF1β-high OCCC cells, which may also contribute 
to the ROS resistance of these cells. To explore the 
mechanism of the higher GSH levels in HNF1β-high 
OCCC cells, we measured GSS, GCLC and GCLM, the 
enzymes that produce GSH, but found no significant 
difference between HNF1β-high and low OCCC cells 
(Fig. 6d & 6e). Recently, several reports have shown that 
chemo-resistant tumor cells, including cancer stem cells, 
increase intracellular GSH through the cystine transporter 
xCT [17, 18, 44, 45]. In our experiment, cystine levels 
were associated with the amount of GSH in OCCC cells 
(Fig. 7a). However, we found no upregulation of xCT 
expression in HNF1β-high OCCC cells. Instead, we found 
that another cystine transporter, rBAT (Related to b0,+ 
Amino acid Transporter), was expressed at significantly 
higher levels in these cells (Fig. 6f). rBAT is coded by 
rBAT / SLC3A1 which is well known as the responsible 
gene of type I cystinuria. Heterodimer of rBAT and 
BAT1 (b0,+AT), which is coded by SLC7A9, transports 
cystine and dibasic amino acids, such as lysine, arginine, 
and ornithine, and thus is critical for reabsorption of these 
amino acids in the proximal tubule. With regard to the 
relation of HNF1β and rBAT, Sauert K. et al. reported that 
HNF1β mutation decreased rBAT expression [46]. And 
the results of our metabolome analysis that intracellular 
lysine, arginine, and ornithine were significantly higher 
in HNF1β-high cells (Fig. S2) is compatible for high 
expression of rBAT in HNF1β-high OCCC cells. 
Furthermore, knockdown of rBAT by sh-RNA resulted 
in decreased levels of intracellular GSH and increased 
ROS activity both with and without oxidative stress 
(Fig. 7d – 7f), suggesting that rBAT plays a major role in 
HNF1β-triggered ROS resistance in OCCC cells. This is 
the first report to show the importance of rBAT in survival 
of cancer cells.
In conclusion, we have demonstrated that HNF1β 
drastically changes glucose and amino acid metabolism 
and that it promotes cell survival in hypoxic conditions 
under oxidative stress. These results are compatible with 
the fact that most OCCCs originate in endometriotic cysts 
and survive under severely oxidative conditions [11]. It 
is well known that OCCC is resistant to conventional 
chemotherapy and that a novel therapeutic modality is 
needed. Our findings here may provide several new clues 
to aid in the treatment of this disease (Fig. S6). First, 
HNF1β-induced aerobic glycolysis increased stress-
resistance, hypoxia adaptation, and consequent survival 
capacity of OCCC, but these effects are highly glucose-
dependent. In our assay, actually, the control RMG2 cells 
with higher HNF1β expression were more sensitive to 
glucose deprivation than were HNF1β knockdown cells, 
indicating that glucose uptake and metabolism may be a 
therapeutic target in OCCC. Secondly, HNF1β inhibition 
with some type of inhibitor, such as the microRNA mir-
802 [51], may have a therapeutic effect by abrogating 
ROS resistance in OCCC. Finally, an inhibitor of GSH 
synthesis, such as buthionine sulfoximine [52, 53], or 
inhibition of GSH synthesis by targeting the cystine 
transporter rBAT, may enhance the effect of conventional 
chemotherapy. Further study is needed to explore the 
potential of these therapeutic applications.
MATERIALS AND METHODS
Cell lines and cell culture
The OCCC cell line RMG2 was kindly provided 
by Dr. Aoki at Keio University, and the OCCC cell line 
JHOC5 was purchased from the Riken BioResource 
Center. Cells were cultured in RPMI1640 medium 
(Nacalai Tesque, Kyoto, Japan) supplemented with 10% 
fetal bovine serum (FBS) (Biowest, Courtaboeuf Cedex, 
France) and penicillin–streptomycin (Nacalai Tesque) in a 
humidified atmosphere containing 5% CO2 at 37°C.
RMG2 and JHOC5 knockdown cells were 
generated by lentiviral transfection using two 
different GIPZ Lentiviral shRNAs and a nonsilencing 
control RNA (Thermo Scientific, Waltham, MA) 
(cone name/ sh RNA clone ID/ antisense sequence: 
HNF1β_ sh1/ V2LHS_204881/ TGAATTGTCGGAGGA 
TCTC, HNF1β_sh2/ V3LHS_409658/ AGTTTATAG 
TTTACAGCCA, rBAT- sh1/ V2LHS_229777/ TATGTT 
TATCACTCGTGTG, rBAT- sh2/ V3LHS_311025/ ATTG 
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TGTGACCGTGTCCGG, control/ RHS4348 ). We used 
10 μg /ml puromycin for selection and confirmed that 
over 95% of cells were successfully transfected with RNA 
based on GFP fluorescence by fluorescence microscopy. 
We checked the transfection efficacies of HNF1β and 
rBAT by RT-PCR and western blotting (Fig. S4a, S4b, 
S4c, & S4d).
Real-time polymerase chain reaction (RT-PCR)
Total RNA was isolated using the RNeasy Mini Kit 
(Qiagen, Tokyo, Japan), treated with the PrimeScript™ 
RT reagent Kit (Takara, Shiga, Japan), and analyzed 
using Light Cycler 480 Real-Time PCR system (Roche, 
Basel, Switzerland). The HNF1β, rBAT and HPRT1 
(housekeeping gene) primers and probes were designed 
using Roche Universal ProbeLibrary Assay Design Center 
software (http://qpcr.probefinder.com/roche3.html) (gene 
name/ assession number/ antisense primer sequence/ 
sense primer sequence/ Roche Universal Probe # : 
HNF1β/ NM_000458.2/ caccaacatgtcttcaagtaaacag/ 
ttgttgcgcacgaagtaagt/ 9, rBAT/ NM_000341.3/ accacactgtg 
aatgttgatgtc/ agtagctcattggcatgaagtaga/ 26, HPRT1/ 
NM_000194.2/ tgaccttgatttattttgcatacc/ cgagcaagacgttc 
agtcct/ 73).
Intracellular ROS analysis
Each cell culture, both with and without oxidative 
stress, was washed twice with PBS and then stained with 
5 μM CellROX® Deep Red Reagent (Life Technologies, 
Japan, Tokyo) with complete medium at 37°C for 
30 minutes. The cells were then harvested and washed 
with PBS and analyzed using a FACSCalibur cytometer 
(Becton Dickinson, Franklin Lakes, NJ). The results 
were analyzed using FlowJo_V10 software. Differences 
between groups were assessed based on the mean 
fluorescence intensity (MFI) of FL4.
Intracellular GSH and GSSG analysis
GSH was measured using a GSH/ GSSG quantifi-
cation assay kit (Dojindo, Kumamoto, Japan), based on 
the enzymatic recycling method. Cultured cells were har-
vested, treated, measured by absorption spectrometer, and 
quantified according to the manufacturer’s manual. (http://
www.dojindo.com/store/p/824-GSSG-GSH-Quantifica-
tion-Kit.html).
Comprehensive analysis of intracellular 
metabolites
RMG2_HNF1β_sh1 cells and RMG2_control cells 
cultured with complete medium (D-glucose 2000 mg / l, 
L-glutamine 300 mg / l, glutathione 1 mg / l, lactate 
0 mg / l , and pyruvate 0 mg / l) at 37°C in 20% O2 and 
5% CO2 were washed by mannitol solution, quenched by 
methanol and collected. Then, 5 × 106 cells from each 
condition were diluted with 1000 μl chloroform and 
400 μl distilled water, and then centrifuged at 2300 × g 
for 5 minutes at 4°C. Replicate 400 μl aliquots of each 
supernatant (for anion/cation) were centrifuged at 9100 × g 
for 120 minutes at 4°C using a 5 kDa ultrafiltration 
membrane (Millipore, Billerica, MA). The supernatant 
from each sample was solidified, re-diluted with 50 μl 
distilled water, and measured by CE-TOFMS (Capillary 
electrophoresis electrospray ionization time-of-flight 
mass spectrometry). This measurement was performed by 
Human Metabolome Technologies (HMT) Inc. (Yamagata, 
Japan). Based on HMT’s database of the mass-to-charge 
ratio (m/z) and the migration time (MT) of peaks detected 
in CE-TOFMS, 193 peaks were assigned to candidate 
metabolites. Of these 193 metabolites, 87 were quantified 
using integrated peak areas obtained from measurements 
of chemical standards that were analyzed in parallel with 
experimental samples. Others were compared using their 
relative peak areas. Data were analyzed using previously 
reported methods [54, 55].
Microarray analysis
GSE39204 [56], which contained clinical ovarian 
cancer specimens from 64 patients (16 OCCC and 48 
non-OCCC (29 serous, 13 endometrioid, 2 mucinous, 
and 4 others)) who underwent primary surgery at Kyoto 
University Hospital between 1997 and 2011, was used for 
GSEA and analysis of metabolic-related gene expression.
GSE6008, which was uploaded to publicly 
available online databases by Wu R et al. and contained 
99 individual ovarian tumors (8 OCCC and 91 non-
OCCC (41 serous, 37 endometrioid, 13 mucinous, and 
4 individual normal ovary samples)) [30], was also used 
for GSEA.
GSE37290 [25], a microarray dataset of 
RMG2 HNF1β_sh1 cells and RMG2 control cells, was 
also analyzed to evaluate the relevance of HNF1β to 
metabolic function in OCCC.
Total RNA expression was analyzed on the HG U133 
Plus 2.0 Array (Affymetrix) (GSE39204 and GSE37290) 
and the HG_U133A array (Affymetrix) (GSE6008). The 
expression intensities were normalized across all samples 
using the robust multichip average algorithm [57]. Gene 




Whole cell lysates were prepared for western blot 
analysis. Equal amounts of protein were electrophoresed 
on SDS–PAGE gels and transferred to polyvinylidene 
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fluoride membranes (Bio-Rad). Then, they were probed 
with the following antibodies: HNF1β (sc-7411, 1:200; 
Santa Cruz Biotechnology, Dallas, TX); rBAT/ SLC3A1 
(ab104691, 1:200, Abcam); β-Actin (ab8227, 1:3000, 
Abcam), and visualized by Chemi-Lumi One (Nacalai 
Tesque) and the ChemiDoc™ XRS+ system (Bio-Rad, 
Hercules, CA).
Oxidative stress / CDDP resistance analysis
Oxidative stress resistance was assessed by MTT 
assay using WST-8 (Cell Count Reagent SF, Nacalai 
Tesque) after treatment with oxidative agents (ferric 
nitrilotriacetate or hydrogen peroxide) or CDDP. The 
concentration of oxidative agents required to inhibit cell 
proliferation by 50% (IC50) was calculated using Prism 5 
software (GraphPad, California, USA).
Cell proliferation under hypoxia
Cells were pre-cultured in 20% O2 for 24 hours and 
then in either 2% O2 (hypoxia) or 20% O2 (normoxia). Cell 
proliferation under hypoxia and normoxia was assessed by 
MTT assay using WST-8 (Cell Count Reagent SF) every 
24 hours.
Glucose deprivation assay
Cells were pre-cultured in complete medium 
(D-glucose 2000 mg / l, L-glutamine 300 mg / l, 
glutathione 1 mg / l, lactate 0 mg / l , and pyruvate 
0 mg / l) at 37°C in 20% O2 and 5% CO2 for 72 hours 
as previously described and then cultured in either 
glucose (+) medium (D-glucose 2000 mg / l, L-glutamine 
300 mg / l, glutathione 1 mg / l, lactate 0 mg / l , and 
pyruvate 0 mg / l, Nacalai RPMI1640 cat. no. 30264), 
or glucose (−) medium (D-glucose 0 mg / l, L-glutamine 
300 mg / l, glutathione 1 mg / l, lactate 0 mg / l , and 
pyruvate 0 mg / l, Nacalai RPMI1640 cat. no. 09892). 
Both media were supplemented with 10% FBS and 
contained the same formulation except for the presence or 
absence of D-glucose. Cell proliferation was assessed by 
MTT assay using WST-8 (Cell Count Reagent SF) every 
24 hours.
Statistical analyses
Statistical significance was assessed by two-tailed 
unpaired t-tests using Prism 5 software (GraphPad), and 
p values of < 0.05 were considered statistically significant. 
Data are shown as the mean  ±  standard deviation (SD).
Abbreviations
HNF1β, hepatocyte nuclear factor 1β; OCCC, 
ovarian clear cell carcinoma, ROS; reactive oxygen 
species; GSH, glutathione; GSEA, gene set enrichment 
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